Get started
ALNYLAM PHARMACEUTALNYLAM PHARMACEUTALNYLAM PHARMACEUT

ALNYLAM PHARMACEUT

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

DUL chart


Full chart

DUL upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪26.72 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.221 CHF
Net income (FY)
‪−370.66 M‬ CHF
Revenue (FY)
‪1.54 B‬ CHF
Shares float
‪127.95 M‬
Beta (1Y)
0.92

Employees


Employees (FY)
‪2.1 K‬
Change (1Y)
+98 +4.90%
Revenue / Employee (1Y)
‪870.62 K‬ CHF
Net income / Employee (1Y)
‪−209.64 K‬ CHF

About Alnylam Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Website
alnylam.com
Founded
2002
FIGI
BBG00LVD60G6
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

DUL news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

DUL highest yielding bonds


ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027
Yield to maturity
−2.10%
Maturity date
Sep 15, 2027

Explore more bonds 

Sparks


Curated watchlists where DUL is featured.

See all sparks 

Frequently Asked Questions


The current price of DUL is 219.993 CHF — it has decreased by −6.71% in the past 24 hours. Watch ALNYLAM PHARMACEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ALNYLAM PHARMACEUT stocks are traded under the ticker DUL.
DUL stock has fallen by −6.71% compared to the previous week, the month change is a −5.99% fall, over the last year ALNYLAM PHARMACEUT has showed a 35.88% increase.
We've gathered analysts' opinions on ALNYLAM PHARMACEUT future price: according to them, DUL price has a max estimate of 349.04 CHF and a min estimate of 155.32 CHF. Watch DUL chart and read a more detailed ALNYLAM PHARMACEUT stock forecast: see what analysts think of ALNYLAM PHARMACEUT and suggest that you do with its stocks.
DUL reached its all-time high on Nov 8, 2024 with the price of 235.815 CHF, and its all-time low was 132.022 CHF and was reached on Apr 24, 2024. View more price dynamics on DUL chart.
See other stocks reaching their highest and lowest prices.
DUL stock is 7.19% volatile and has beta coefficient of 0.92. Track ALNYLAM PHARMACEUT stock price on the chart and check out the list of the most volatile stocks — is ALNYLAM PHARMACEUT there?
Today ALNYLAM PHARMACEUT has the market capitalization of ‪26.72 B‬, it has decreased by −5.48% over the last week.
Yes, you can track ALNYLAM PHARMACEUT financials in yearly and quarterly reports right on TradingView.
ALNYLAM PHARMACEUT is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
DUL earnings for the last quarter are −0.74 CHF per share, whereas the estimation was −0.78 CHF resulting in a 5.09% surprise. The estimated earnings for the next quarter are −0.52 CHF per share. See more details about ALNYLAM PHARMACEUT earnings.
ALNYLAM PHARMACEUT revenue for the last quarter amounts to ‪424.49 M‬ CHF, despite the estimated figure of ‪451.60 M‬ CHF. In the next quarter, revenue is expected to reach ‪512.61 M‬ CHF.
DUL net income for the last quarter is ‪−94.55 M‬ CHF, while the quarter before that showed ‪−15.18 M‬ CHF of net income which accounts for −522.69% change. Track more ALNYLAM PHARMACEUT financial stats to get the full picture.
No, DUL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has ‪2.10 K‬ employees. See our rating of the largest employees — is ALNYLAM PHARMACEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALNYLAM PHARMACEUT EBITDA is ‪−111.98 M‬ CHF, and current EBITDA margin is −12.48%. See more stats in ALNYLAM PHARMACEUT financial statements.
Like other stocks, DUL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALNYLAM PHARMACEUT stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALNYLAM PHARMACEUT technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALNYLAM PHARMACEUT stock shows the buy signal. See more of ALNYLAM PHARMACEUT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.